.tb-container[data-toolset-blocks-container="8c13577c35fd68d7b70a2a5270dfdf0d"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-container[data-toolset-blocks-container="93f4094e2a5fc591c3cbd3f80a56f302"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 1px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] { text-align: center; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px -5px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__content { text-shadow: 5px 5px 10px rgba( 0, 0, 0, 0.5 );color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon { font-family: dashicons;margin-right: 10px; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon::before { content: '\f103'; } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="d8ee833869d806ba93519c93a0c99d68"] { border-top: 1px dotted rgba( 0, 0, 0, 1 );border-right: 0px dashed rgba( 0, 0, 0, 1 );border-bottom: 0px dashed rgba( 0, 0, 0, 1 );border-left: 0px dashed rgba( 0, 0, 0, 1 ); } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] { text-align: center; } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__icon { font-family: dashicons; } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] { text-align: center; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__icon { font-family: dashicons; } @media only screen and (max-width: 781px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } @media only screen and (max-width: 599px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } 
Báo cáo thường niên năm 2019 của Abeona Therapeutics Inc
Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.
TÊN CÔNG TY / COMPANY
Abeona Therapeutics Inc
SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)
MÃ CHỨNG KHOÁN / TICKER
ABEO
KỲ BÁO CÁO
2019
NGÀNH / INDUSTRY
Biotechnology
LĨNH VỰC / SECTOR
Healthcare
Có thể bạn quan tâm:
Báo cáo thường niên của Crescita Therapeutics Inc. năm 2019
Báo cáo thường niên của Knight Therapeutics Inc. năm 2019
Báo cáo thường niên của Trillium Therapeutics Inc. năm 2019
Báo cáo thường niên của Acorda Therapeutics, Inc. năm 2019
Báo cáo thường niên của Agile Therapeutics Inc năm 2019
Báo cáo thường niên của Amicus Therapeutics, Inc. năm 2019
Báo cáo thường niên của Anika Therapeutics Inc. năm 2019
Báo cáo thường niên của Cara Therapeutics Inc năm 2019
Báo cáo thường niên của Cell Therapeutics Inc. năm 2019
Báo cáo thường niên của Celldex Therapeutics Inc. năm 2019
Báo cáo thường niên của Cidara Therapeutics Inc năm 2019
Báo cáo thường niên của Esperion Therapeutics Inc năm 2019